The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro.
Ciprofloxacin was found to be the most active of a group of 4-quinolone antibiotics tested against the SA2f strain of Chlamydia trachomatis (MBC and MIC 1.0 mg/l). Against genital isolates of Chlamydia trachomatis, ciprofloxacin was twice as active as rosoxacin. Ciprofloxacin showed similar activity to that of oxytetracycline against clinical isolates of Mycoplasma hominis and Ureaplasma urealyticum, and was 8-fold more active than rosoxacin against the latter.
D042462:4-Quinolones; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002692:Chlamydia trachomatis / Q000187:drug effects*; D002939:Ciprofloxacin; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008826:Microbial Sensitivity Tests; D009174:Mycoplasma / Q000187:drug effects*; D009268:Nalidixic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D009643:Norfloxacin; D010093:Oxolinic Acid / Q000494:pharmacology; D010118:Oxytetracycline / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology*; D015363:Quinolones; D014509:Ureaplasma / Q000187:drug effects
D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D011804:Quinolines; D015363:Quinolones; D009268:Nalidixic Acid; C021083:rosoxacin; D002939:Ciprofloxacin; D010093:Oxolinic Acid; D009643:Norfloxacin; D010118:Oxytetracycline